Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Oxnard · SciRah

Researcher profile · Semantic Scholar

G. Oxnard

Share profile

G. Oxnard — researcher profile on SciRah

h-index: 67
Works: 405
Citations: 21K

Most-cited papers

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Jessica K. Lee, S. Sivakumar, A. Schrock, R. Madison +14 more
2022npj Precision Oncology173 citations Open access
Semantic Scholar
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study
Z. Reichert, T. Morgan, G. Li, E. Castellanos +7 more
2022Annals of Oncology169 citations Open access
Semantic Scholar
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
Z. Assaf, W. Zou, A. Fine, M. Socinski +15 more
2023Nature Medicine145 citations Open access
Semantic Scholar
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
H. Husain, D. Pavlick, Bernard Fendler, R. Madison +10 more
2022JCO Precision Oncology108 citations Open access
Semantic Scholar
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.
L. Dercle, Binsheng Zhao, M. Gönen, C. Moskowitz +13 more
2022JAMA Oncology91 citations Open access
Semantic Scholar
Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Xiao-Ji Chen, Zhao Dong, E. Hubbell, K. Kurtzman +11 more
2021Clinical Cancer Research85 citations Open access
Semantic Scholar
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
K. Chi, A. Barnicle, Caroline Sibilla, Z. Lai +14 more
2022Clinical Cancer Research76 citations Open access
Semantic Scholar
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
R. Graf, V. Fisher, J. Weberpals, O. Gjoerup +14 more
2022JAMA Network Open66 citations Open access
Semantic Scholar
Genomic landscape of 891 RET fusions detected across diverse solid tumor types
Vamsi Parimi, K. Tolba, N. Danziger, Zheng Kuang +7 more
2023npj Precision Oncology64 citations Open access
Semantic Scholar
Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
J. Rotow, Jessica K. Lee, R. Madison, G. Oxnard +2 more
2023Journal of Thoracic Oncology58 citations Open access
Semantic Scholar
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
J. Gray, M. Ahn, G. Oxnard, F. Shepherd +18 more
2023Clinical Cancer Research57 citations
Semantic Scholar
SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
U. Swami, R. Graf, R. Nussenzveig, V. Fisher +10 more
2022Clinical Cancer Research56 citations
Semantic Scholar
Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
J. Maule, L. Clinton, R. Graf, Jinpeng Xiao +3 more
2022Journal for ImmunoTherapy of Cancer56 citations Open access
Semantic Scholar
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
K. Kehl, D. Zahrieh, Ping Yang, S. Hillman +13 more
2022JAMA Oncology52 citations Open access
Semantic Scholar
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
J. Quintanilha, M. Storandt, R. Graf, Gerald Li +8 more
2023JCO Precision Oncology49 citations Open access
Semantic Scholar
Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry and testing patterns.
Mason A. Israel, N. Danziger, K. McGregor, K. Murugesan +9 more
2021The Oncologist47 citations Open access
Semantic Scholar
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.
R. Heist, T. Koyama, Y. Murciano-Goroff, A. Hollebecque +16 more
2024Journal of Clinical Oncology43 citations
Semantic Scholar
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer
S. Sivakumar, Dexter X. Jin, H. Tukachinsky, K. Murugesan +16 more
2022Nature Communications42 citations Open access
Semantic Scholar
Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
J. Rotow, J. Patel, M. Hanley, H. Yu +14 more
2023Clinical Cancer Research39 citations Open access
Semantic Scholar
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
J. Quintanilha, R. Graf, V. Fisher, G. Oxnard +8 more
2023JAMA Network Open39 citations Open access
Semantic Scholar
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
B. Pellini, R. Madison, Merrida A. Childress, S. Miller +14 more
2023Clinical Cancer Research38 citations Open access
Semantic Scholar
Germline EGFR mutations and familial lung cancer
G. Oxnard, Ruthia Chen, Jennifer C Pharr, Diane R. Koeller +19 more
2023Journal of Clinical Oncology38 citations Open access
Semantic Scholar
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.
Yutaka Fujiwara, T. Burns, K. Dragnev, Y. Murciano-Goroff +16 more
2024Journal of Clinical Oncology36 citations Open access
Semantic Scholar
Prevalence of UV Mutational Signatures Among Cutaneous Primary Tumors
Douglas A. Mata, Erik A. Williams, E. Sokol, G. Oxnard +3 more
2022JAMA Network Open34 citations Open access
Semantic Scholar
Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma
K. Bosse, A. Giudice, M. Lane, B. McIntyre +19 more
2022Cancer Discovery34 citations Open access
Semantic Scholar
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
H. Rugo, K. Raskina, A. Schrock, R. Madison +7 more
2022Clinical Cancer Research33 citations Open access
Semantic Scholar
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response
J. Moore, Kuei-Ting Chen, R. Madison, J. Newberg +14 more
2023JCO Precision Oncology31 citations Open access
Semantic Scholar
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
R. Huang, D. Carbone, Gerald Li, A. Schrock +8 more
2023Journal for ImmunoTherapy of Cancer30 citations Open access
Semantic Scholar
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse
I. Dagogo-Jack, G. Oxnard, M. Evangelist, S. Digumarthy +7 more
2022JCO Precision Oncology30 citations Open access
Semantic Scholar
Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN
S. Mishima, Yoshiaki Nakamura, H. Tukachinsky, H. Taniguchi +19 more
2023The journal of liquid biopsy26 citations Open access
Semantic Scholar
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC
L. Schwartzberg, Gerald Li, K. Tolba, A. Bourla +7 more
2022JTO Clinical and Research Reports25 citations Open access
Semantic Scholar
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
Yoshihisa Kobayashi, G. Oxnard, Elizabeth F Cohen, N. Mahadevan +19 more
2022Nature Communications24 citations Open access
Semantic Scholar
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing
N. Tung, K. Dougherty, Emily Stern Gatof, Kim DeLeonardis +6 more
2023npj Precision Oncology23 citations Open access
Semantic Scholar
Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
E. Antonarakis, Marni B. Tierno, V. Fisher, H. Tukachinsky +6 more
2022The Prostate21 citations Open access
Semantic Scholar
Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR
Drew F. K. Williamson, Sean R N Marris, V. Rojas-Rudilla, J. L. Bruce +4 more
2022PLoS ONE20 citations Open access
Semantic Scholar
Quantifying the value of multi-gene testing in resected early-stage lung adenocarcinoma.
B. Muthusamy, K. Raskina, K. Lofgren, Gerald Li +7 more
2022Journal of Thoracic Oncology20 citations Open access
Semantic Scholar
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
Dong-Wan Kim, S. Gadgeel, S. Gettinger, Gregory Riely +10 more
2022JTO Clinical and Research Reports20 citations Open access
Semantic Scholar
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma.
R. Graf, V. Fisher, R. Huang, O. Hamdani +6 more
2022JCO Precision Oncology20 citations Open access
Semantic Scholar
Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab
Maya Kansara, N. Bhardwaj, S. Thavaneswaran, Changliang Xu +11 more
2022Molecular Oncology18 citations Open access
Semantic Scholar
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies
A. Zurita, R. Graf, G. Villacampa, K. Raskina +12 more
2022JCO Precision Oncology17 citations Open access
Semantic Scholar
Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer.
Douglas A. Mata, L. Harries, Erik A. Williams, M. Hiemenz +17 more
2022Archives of Pathology & Laboratory Medicine17 citations Open access
Semantic Scholar
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
A. Chehrazi-Raffle, H. Tukachinsky, Eamon Toye, S. Sivakumar +10 more
2023Clinical Cancer Research16 citations Open access
Semantic Scholar
ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma
Liangliang Zhang, O. Hamdani, O. Gjoerup, C. Cho-Phan +8 more
2022JCO Precision Oncology16 citations Open access
Semantic Scholar
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC.
T. Burns, N. Ammakkanavar, A. Hollebecque, Dae Ho Lee +21 more
2025Journal of Thoracic Oncology15 citations Open access
Semantic Scholar
BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
J. Quintanilha, R. Graf, G. Oxnard
2023The Oncologist15 citations Open access
Semantic Scholar
Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens
M. Hiemenz, R. Graf, Kelsie Schiavone, L. Harries +3 more
2022The Oncologist14 citations Open access
Semantic Scholar
Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital.
Laura Burns, C. Jani, A. Radwan, O. Al-Omari +3 more
2022Clinical Lung Cancer13 citations
Semantic Scholar
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
D. Gandara, N. Agarwal, Shilpa Gupta, S. Klempner +16 more
2023Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay
T. Powles, Amanda Young, H. Nimeiri, R. Madison +17 more
2023Frontiers in Oncology11 citations Open access
Semantic Scholar
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).
C. Rolfo, R. Madison, L. Pasquina, Derek W Brown +4 more
2023Journal of Clinical Oncology10 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Graf×15
Invite
R. Graf — researcher profile on SciRah
A. Schrock×14
Invite
A. Schrock — researcher profile on SciRah
J. Ross×14
Invite
J. Ross — researcher profile on SciRah
R. Huang×14
Invite
R. Huang — researcher profile on SciRah

×11

Invite

R. Madison — researcher profile on SciRah

Invite

O. Gjoerup — researcher profile on SciRah

H. Tukachinsky×9

Invite

H. Tukachinsky — researcher profile on SciRah

Invite

Gerald Li — researcher profile on SciRah

Invite

E. Sokol — researcher profile on SciRah

Invite

V. Fisher — researcher profile on SciRah

Jessica K. Lee×5

Invite

Jessica K. Lee — researcher profile on SciRah

Invite

G. Frampton — researcher profile on SciRah